Thalidomide was used in human therapy as a sedative, but was withdrawn from the market in the early 60s because of its teratogenic effects. The teratogenic mechanism of action of thalidomide has remained elusive, but bioactivation of thalidomide or its hydrolysis products is thought to be necessary for its teratogenic action. 1 The number of possible metabolites and degradation products of thalidomide exceeds a hundred. Among them, 5′-hydroxythalidomide (1) was identified as an in vitro metabolite by incubation with rat liver homogenates and also as an in vivo metabolite in humans. 2 In this paper, we describe the crystal structure of 5′-hydroxythalidomide.
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The cis-isomer of 1 was synthesized as a racemate from the protected lactone 2 as previously described (Scheme 1).
3 Five milligrams of 1 were dissolved in approximate 0.3 ml acetonitrile by boiling and crystals were grown from this solution at room temperature for a night. The single crystal was mounted on a Hampton nylon loop with 90% glycerol under a nitrogen stream at 90 K. The data collection was performed on a Bruker AXS SMART APEX area detector covering the full sphere of 0.75 Å resolution (Table 1) . A total of 9927 reflections were integrated by the image processing with the 3.33 redundancy and 95.6% completeness, and were merged to 2770 reflections for the monoclinic system with Rint of 0.0234. The structure was solved by SHELXS-97 and refined anisotropically by SHELXL-97 (Table 2) . Hydrogen atoms were calculated at the ideal positions by the ride-on method. A hydrogen atom of the hydroxy group (O5′) was found from a difference Fourier map and was refined with an isotropic temperature factor.
The structure of 1 is shown in Fig. 1 . The second chirality appears at 5′-position by the hydroxylation. The spontaneous inversion is known for the 3′-configuration of thalidomide. 1 There is a possibility of cis-trans isomerization for the hydroxy group by the electron withdrawing effects of the adjacent 6'-carbonyl group, but no trans-isomer is found in the crystal. The phthalimide residues (C1→C7a) are almost coplanar, but the shifts of -0.036(2) and 0.042(1)Å from the least-square plane are observed for the C1 and N2 atoms, respectively, indicating a slight puckering of the five-membered ring (C1-N2-C3-C3a-C7a).
The phthalimide and glutarimide (N1′→C6′) residues are rotated around the N2-C3′ bond, and the angle between their least-square planes is 83.52(6)˚, similar to that of the thalidomide structure (81.3˚). 4 The molecules are linked by hydrogen bonds between the glutarimide residues (N1′···O6′), making the eight-membered ring (Fig. 2) . The 5'-hydroxy group (O5′) is also hydrogen-bonded to the carbonyl oxygen (O3) of the phtalimide residue (Table 3) . When the conformations of 1 and thalidomide are compared, the torsion angles of the glutarimide residue show only slight differences of 5 -9˚ around the C4′-C5′ and C5′-C6′ bonds (Table 4) . Therefore, the 5′-hydroxylation results in no significant change for the rotation around the N2-C3′ bond and the puckering of glutarimide residue. Table 3 Hydrogen bonding geometry (Å, ˚)
Symmetry code: (i) 1/2-x, 1/2-y, 1-z, (ii) x, y-1, z. 
